AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research

AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer Perform from Outperform on January 8 by Wolfe Research without a price target. The firm stated that the shares already reflect outperformance expectations in Skyrizi and Rinvoq, which is why it is moving to the sidelines waiting for higher visibility on the company’s immunology and inflammation “encore” and competitive dynamics.

In a separate development, Reuters reported on January 7 that AbbVie Inc. (NYSE:ABBV) denied its involvement in talks for the acquisition of Revolution Medicines. The update came after the Wall Street Journal reported that AbbVie Inc. (NYSE:ABBV) was in advanced discussions to buy Revolution Medicines, the cancer-drug developer. AbbVie Inc. (NYSE:ABBV) told Reuters in an emailed statement that it “is not in discussions with Revolution Medicines”.

The same day, UBS assumed coverage of AbbVie Inc. (NYSE:ABBV) with a Neutral rating, lifting the price target on the stock to $240 from $220. It told investors that it believes the company is fairly priced at current levels, and sees a balanced risk/reward for the company’s shares as competition emerges for its blockbuster immunology drugs Skyrizi and Rinvoq in 2026 and 2027.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.